Hemony Pharmaceutical Co., Ltd. has gradually grown into a whole industrial chain enterprise that integrates R&D, manufacturing and sales of drugs and medical devices. Registered in Lhasa Economic and Technological Development Zone, Tibet, Hemony is also headquartered in Shanghai and Chongqing, with subsidiaries located in Hong Kong, Taiwan, Germany, Switzerland and other countries and regions.

As a pioneer to practice the Marketing Authorization Holder (MAH) system in domestic China, Hemony has a wealth of experience in merging and acquiring mature pharmaceutical assets from multinational pharmaceutical companies. In recent years, our company has merged and acquired the superior products of numerous multinational pharmaceutical corporations, including Novartis' Baclofen Tablets in Switzerland, Wyeth's Multivitamin Elemental Tablets in the United States, Takeda's Calcium Carbonate D3 Chewable Tablets in Japan, STADA's Lipoic Acid Injection in Germany, Herbrand's Propylthiouracil Tablets in Germany, Lotuspharm’s Mesyrel in Taiwan region, Synmosa’s Budesonide Nasal Spray in Taiwan region, etc.

The corporation has targeted fields of psychiatry, ENT, obstetrics and gynecology, orthopedics and other disease areas, as well as other disease areas, with a sales team with differentiated coverage in urban hospitals, county medical institutions and grassroots public hospitals; Moreover, covering multiple channels such as KA chains, small and medium-sized chains and specialty clinics offline while to enduser and to business entities and other online channel.

With the mission of “All Efforts for Health”, with the vision of “Strive to become a medical enterprise with leading commercialization capabilities, highly respected in the industry, and all employees who feel happy", with core value of “Be highly aimed and pragmatic, be innovative and tolerant, be cooperative&honest and trustworthy”, Hemony will always exert to provide people with high quality pharmaceutical products and services.